Topical Allstate and Nasal Allergen Challenge

Phase 3

Withdrawn

• Conditions: Allergic Rhinitis
• Interventions: Device: Allstate Nasal Spray; Device: Placebo Nasal Spray

• Registration Number: NCT01231724
• Lead Sponsor: University of Chicago

Brief Summary

The purpose of this study is to see whether Allstate Nasal Spray when given in the nose is safe and can reduce the signs and symptoms of allergic rhinitis (hayfever).

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2010-10-28
• Study First Submitted QC: 2010-10-28
• Study First Posted: 2010-11-01
• Study Start: 2011-11
• Primary Completion: 2012-02
• Study Completion: 2012-04
• Status Verified: 2013-05
• Last Update Submitted: 2013-05-30
• Last Update Posted: 2013-06-03

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Allstate Nasal Spray	Allstate Nasal Spray	-
Placebo Nasal Spray	Placebo Nasal Spray	-

Primary Outcome Measures

Name	Time	Method
Number of sneezes and total nasal symptom score (TNSS) (sum of nasal stuffiness, nasal discharge, and nasal itching) (scale 0-3 for each symptom; total score 0-9) are co-primary endpoints.	10 minutes following each nasal challenge

Trial Locations

Locations (1)

University of Chicago; 🇺🇸 Chicago, Illinois, United States